Literature DB >> 17761156

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275.

Manjula Reddy1, Cuc Davis, Jackson Wong, Paul Marsters, Charles Pendley, Uma Prabhakar.   

Abstract

Cytokines interleukin (IL)-12 and IL-23 are implicated in the pathogenesis of psoriasis. IL-12 causes differentiation of CD4+ T cells to interferon-gamma (IFN-gamma)-producing T helper 1 (Th1) cells, while IL-23 induces differentiation to IL-17-producing pathogenic Th17 cells. The effects of the monoclonal antibody to IL-12/23 p40 subunit (CNTO 1275) on IL-12 receptor (IL-12R) expression, markers associated with skin homing, activation, and cytokine secretion were investigated in vitro using human peripheral blood mononuclear cells (PBMCs) from healthy donors. PBMCs were activated in the presence or absence of recombinant human (rh) IL-12 or rhIL-23, with or without CNTO 1275. CNTO 1275 inhibited upregulation of CLA, IL-12R, IL-2Ralpha and CD40L expression and also inhibited IL-12- and IL-23-induced IFN-gamma, IL-17A, tumor necrosis factor (TNF)-alpha, IL-2, and IL-10 secretion. Thus, the therapeutic effect of CNTO 1275 may be attributed to the IL-12/23 neutralization, resulting in decreased expression of skin homing and activation markers, and IL-12- and IL-23-induced cytokine secretion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761156     DOI: 10.1016/j.cellimm.2007.06.006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  16 in total

1.  Amygdalin analogues inhibit IFN-γ signalling and reduce the inflammatory response in human epidermal keratinocytes.

Authors:  Iole Paoletti; Vincenza De Gregorio; Adone Baroni; Maria Antonietta Tufano; Giovanna Donnarumma; Juan Jesus Perez
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

2.  Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis.

Authors:  Jing Li; Hui Wei; Stanley R Krystek; Derek Bond; Ty M Brender; Daniel Cohen; Jena Feiner; Nels Hamacher; Johanna Harshman; Richard Y-C Huang; Susan H Julien; Zheng Lin; Kristina Moore; Luciano Mueller; Claire Noriega; Preeti Sejwal; Paul Sheppard; Brenda Stevens; Guodong Chen; Adrienne A Tymiak; Michael L Gross; Lumelle A Schneeweis
Journal:  Anal Chem       Date:  2017-02-09       Impact factor: 6.986

3.  T cell-specific STAT3 deficiency abrogates lupus nephritis.

Authors:  N Yoshida; F He; V C Kyttaris
Journal:  Lupus       Date:  2019-09-24       Impact factor: 2.911

Review 4.  Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Authors:  Wolfgang Weger
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Authors:  Chunlei Tang; Shu Chen; Hai Qian; Wenlong Huang
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

Review 6.  Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

Review 7.  Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics.

Authors:  Roxana E Iacob; Stanley R Krystek; Richard Y-C Huang; Hui Wei; Li Tao; Zheng Lin; Paul E Morin; Michael L Doyle; Adrienne A Tymiak; John R Engen; Guodong Chen
Journal:  Expert Rev Proteomics       Date:  2015-02-24       Impact factor: 3.940

Review 8.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

Review 9.  Ustekinumab.

Authors:  Oya Cingoz
Journal:  MAbs       Date:  2009 May-Jun       Impact factor: 5.857

Review 10.  IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities.

Authors:  Jackelyn B Golden; Thomas S McCormick; Nicole L Ward
Journal:  Cytokine       Date:  2013-04-04       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.